Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Does 24R,25(OH)2-vitamin D3 prevent postmenopausal bone loss?

B J Riis, K Thomsen, C Christiansen

Calcified Tissue International

|September 1, 1986

Summary

Oral 24R,25(OH)2-vitamin D3 did not prevent postmenopausal bone loss in a 2-year trial. This vitamin D3 treatment showed no prophylactic effect on bone mineral density or calcium metabolism in early postmenopausal women.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.

Bone·2018

Same author

Cohort Profile: The Prospective Epidemiological Risk Factor (PERF) study.

International journal of epidemiology·2016

Same author

Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials.

Osteoarthritis and cartilage·2015

Same author

OA phenotypes, rather than disease stage, drive structural progression--identification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA.

Osteoarthritis and cartilage·2015

Same author

Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.

Bone·2012

Same author

Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2011

Area of Science:

Endocrinology
Metabolic Bone Disease
Nutritional Science

Background:

Postmenopausal bone loss is a significant health concern.
Vitamin D metabolites are crucial for calcium homeostasis and bone health.
The role of 24R,25(OH)2-vitamin D3 in preventing bone loss requires further investigation.

Purpose of the Study:

To evaluate the efficacy of oral 24R,25(OH)2-vitamin D3 as a prophylactic agent against postmenopausal bone loss.
To assess the impact of 24R,25(OH)2-vitamin D3 on calcium metabolic variables in postmenopausal women.

Main Methods:

A 2-year, double-blind, placebo-controlled therapeutic trial involving 58 healthy, early postmenopausal women.
Randomization to daily 10 microgram 24R,25(OH)2D3 or placebo.
Regular monitoring of bone mineral density (forearm, lumbar spine, total body) and calcium metabolic markers (serum calcium, alkaline phosphatase, urinary hydroxyproline, radiocalcium absorption).

Main Results:

No significant difference in the rate of bone mineral loss was observed between the 24R,25(OH)2-vitamin D3 and placebo groups.
Forearm, lumbar spine, and total body bone mineral content decreased significantly and similarly in both treatment arms.
Serum calcium, alkaline phosphatase, fasting urinary hydroxyproline, 24-hour urinary calcium excretion, and radiocalcium absorption remained unchanged in both groups.

Conclusions:

Oral 24R,25(OH)2-vitamin D3 administration does not offer a prophylactic effect against postmenopausal bone loss.
The treatment did not influence key calcium metabolic variables in the studied population.
Further research may be needed to explore other vitamin D metabolites or therapeutic strategies for postmenopausal osteoporosis.

Related Experiment Videos